Faisal Khurshid
Stock Analyst at Leerink Partners
(1.40)
# 3,358
Out of 4,876 analysts
19
Total ratings
50%
Success rate
-11.1%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRWD Ironwood Pharmaceuticals | Maintains: Market Perform | $3 → $1 | $0.74 | +35.87% | 2 | Apr 14, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $45 | $15.73 | +186.08% | 1 | Apr 8, 2025 | |
| NRIX Nurix Therapeutics | Initiates: Market Perform | $16 | $11.75 | +36.17% | 1 | Mar 17, 2025 | |
| STTK Shattuck Labs | Initiates: Outperform | $4 | $0.96 | +318.41% | 1 | Mar 17, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Market Perform | $33 → $2 | $1.31 | +53.26% | 2 | Mar 3, 2025 | |
| ATYR aTyr Pharma | Initiates: Outperform | $16 | $5.13 | +211.89% | 1 | Feb 18, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $60 | $44.20 | +35.75% | 2 | Dec 27, 2024 | |
| ANIP ANI Pharmaceuticals | Initiates: Outperform | $80 | $65.36 | +22.41% | 1 | Dec 11, 2024 | |
| ZURA Zura Bio | Initiates: Outperform | $15 | $1.14 | +1,221.59% | 1 | Nov 4, 2024 | |
| TRVI Trevi Therapeutics | Assumes: Outperform | $7 | $5.69 | +23.13% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $17.16 | +162.24% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $24 | $28.05 | -14.44% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.51 | +363.58% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $3.74 | +114.19% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $5 | $0.71 | +604.52% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $3.21 | +242.68% | 1 | Mar 21, 2023 |
Ironwood Pharmaceuticals
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $0.74
Upside: +35.87%
Spyre Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $15.73
Upside: +186.08%
Nurix Therapeutics
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $11.75
Upside: +36.17%
Shattuck Labs
Mar 17, 2025
Initiates: Outperform
Price Target: $4
Current: $0.96
Upside: +318.41%
Pliant Therapeutics
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.31
Upside: +53.26%
aTyr Pharma
Feb 18, 2025
Initiates: Outperform
Price Target: $16
Current: $5.13
Upside: +211.89%
Kymera Therapeutics
Dec 27, 2024
Maintains: Outperform
Price Target: $60
Current: $44.20
Upside: +35.75%
ANI Pharmaceuticals
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $65.36
Upside: +22.41%
Zura Bio
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $1.14
Upside: +1,221.59%
Trevi Therapeutics
Sep 9, 2024
Assumes: Outperform
Price Target: $7
Current: $5.69
Upside: +23.13%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $17.16
Upside: +162.24%
Sep 9, 2024
Initiates: Market Perform
Price Target: $24
Current: $28.05
Upside: -14.44%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.51
Upside: +363.58%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $3.74
Upside: +114.19%
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $0.71
Upside: +604.52%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $3.21
Upside: +242.68%